J&J's Stelara settlement streak rolls on with Fresenius Kabi, Formycon deal

By inking a third Stelara patent settlement, Johnson & Johnson is getting more clarity around the forthcoming loss of exclusivity for its top product by sales.

J&J has signed its latest Stelara patent settlement with Fresenius Kabi and Formycon, granting the biosimilar partners a U.S. license date for their drug beginning "no later than April 15, 2025," according to a Monday release.